Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30328% above fair value
$67.79−2.28 (-3.25%)
Close on Nov 18, 2026Market cap $7.33BP/E 161.4Yield –
Corcept Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Corcept Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $106.92M, down 40.8% year over year. For fiscal 2025 it was $141.79M, down 27.7% from the year before. Over ten years it grew 46.5% a year on average. The highest annual figure on record is $196.12M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.79M | -27.7% |
| FY2024 | Dec 31, 2024 | $196.12M | +55.0% |
| FY2023 | Dec 31, 2023 | $126.54M | +5.5% |
| FY2022 | Dec 31, 2022 | $119.91M | -28.4% |
| FY2021 | Dec 31, 2021 | $167.42M | +11.1% |
| FY2020 | Dec 31, 2020 | $150.73M | +11.6% |
| FY2019 | Dec 31, 2019 | $135.03M | +17.0% |
| FY2018 | Dec 31, 2018 | $115.37M | +90.6% |
| FY2017 | Dec 31, 2017 | $60.52M | +232.6% |
| FY2016 | Dec 31, 2016 | $18.20M | +484.5% |
| FY2015 | Dec 31, 2015 | $3.11M | – |
| FY2014 | Dec 31, 2014 | -$27.55M | – |
| FY2013 | Dec 31, 2013 | -$37.19M | – |
| FY2012 | Dec 31, 2012 | -$36.17M | – |
| FY2011 | Dec 31, 2011 | -$27.43M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.02M | -29.9% |
| Q1 FY2026 | Mar 31, 2026 | -$16.97M | -463.8% |
| Q4 FY2025 | Dec 31, 2025 | $38.40M | -35.9% |
| Q3 FY2025 | Sep 30, 2025 | $54.48M | -24.0% |
| Q2 FY2025 | Jun 30, 2025 | $44.24M | +8.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.67M | -80.4% |
| Q4 FY2024 | Dec 31, 2024 | $59.94M | +984.0% |
| Q3 FY2024 | Sep 30, 2024 | $71.66M | +35.5% |
| Q2 FY2024 | Jun 30, 2024 | $40.77M | -3.3% |
| Q1 FY2024 | Mar 31, 2024 | $23.76M | -8.5% |
| Q4 FY2023 | Dec 31, 2023 | $5.53M | -83.4% |
| Q3 FY2023 | Sep 30, 2023 | $52.87M | +58.8% |
| Q2 FY2023 | Jun 30, 2023 | $42.18M | +134.1% |
| Q1 FY2023 | Mar 31, 2023 | $25.96M | -26.3% |
| Q4 FY2022 | Dec 31, 2022 | $33.36M | -32.4% |
| Q3 FY2022 | Sep 30, 2022 | $33.30M | -31.4% |
| Q2 FY2022 | Jun 30, 2022 | $18.02M | -59.2% |
| Q1 FY2022 | Mar 31, 2022 | $35.24M | +39.3% |
| Q4 FY2021 | Dec 31, 2021 | $49.36M | +42.5% |
| Q3 FY2021 | Sep 30, 2021 | $48.55M | +63.3% |
| Q2 FY2021 | Jun 30, 2021 | $44.22M | -16.8% |
| Q1 FY2021 | Mar 31, 2021 | $25.30M | -23.9% |
| Q4 FY2020 | Dec 31, 2020 | $34.64M | -28.3% |
| Q3 FY2020 | Sep 30, 2020 | $29.73M | -22.1% |
| Q2 FY2020 | Jun 30, 2020 | $53.14M | +111.3% |
| Q1 FY2020 | Mar 31, 2020 | $33.23M | +41.9% |
| Q4 FY2019 | Dec 31, 2019 | $48.32M | +125.7% |
| Q3 FY2019 | Sep 30, 2019 | $38.14M | -14.2% |
| Q2 FY2019 | Jun 30, 2019 | $25.15M | +66.0% |
| Q1 FY2019 | Mar 31, 2019 | $23.42M | -31.8% |
| Q4 FY2018 | Dec 31, 2018 | $21.41M | -13.9% |
| Q3 FY2018 | Sep 30, 2018 | $44.46M | +310.0% |
| Q2 FY2018 | Jun 30, 2018 | $15.15M | -1.4% |
| Q1 FY2018 | Mar 31, 2018 | $34.35M | +263.5% |
| Q4 FY2017 | Dec 31, 2017 | $24.85M | +453.0% |
| Q3 FY2017 | Sep 30, 2017 | $10.84M | +22.6% |
| Q2 FY2017 | Jun 30, 2017 | $15.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.45M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.49M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.85M | – |
See a number that looks wrong?